View Post

Evive Biotech Sees Positive Results in Phase III Trial for CIN in Breast Cancer Patients

In Clinical Studies News by Barbara Jacoby

By: Krystle Vermes Source: BioSpace From: Evive Biotech announced today that its Phase III study investigating F-627 to treat chemotherapy-induced neutropenia (CIN) in breast cancer patients has met its primary and secondary endpoints. F-627, also known as efbemalenograstim alpha, works by increasing the production of white blood cells. A low concentration of these cells is a common side effect …